Highlights from 2025 EAU Annual Meeting on Urology

The 40th Annual European Association of Urology Congress (EAU 2025) was held from March 21–24, 2025, in Madrid, Spain. As one of the most anticipated events in the field of urology, the Congress once again brought together thousands of healthcare professionals, researchers, and industry experts from around the world.

This year’s edition featured a dynamic four-day scientific program, offering an engaging mix of live surgeries, state-of-the-art lectures, patient-focused discussions, and hands-on training sessions led by the European School of Urology. The Congress provided a platform for emerging scientists to present their cutting-edge research while equipping young urologists with the knowledge and skills they need for the future.

A highlight of EAU25 was the prestigious Awards Ceremony, where outstanding contributions to the field were recognized. The EAU Willy Gregoir Medal was presented to Prof. Francesco Montorsi (Italy) in honor of his significant efforts in advancing the urological specialty across Europe.

Additionally, the EAU Frans Debruyne Life Time Achievement Award was awarded to Prof. Anders Bjartell (Sweden) for his decades-long dedication and impactful work within the EAU and the broader urological community. Many other distinguished professionals were also honored during the ceremony for their remarkable achievements and service to the field.

Among the scientific highlights was the game-changer session on prostate cancer (PCa),  led by Chairs Prof. Joost Boormans (NL) and Dr. Gianluca Giannarini (IT) featuring updates on the ARANOTE and SPCG-13 trials. Prof. Fred Saad (CA) presented data from ARANOTE, showing that darolutamide plus ADT led to significantly deeper and more durable PSA responses in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared to placebo. He noted the potential need for triplet therapy in patients not achieving undetectable PSA. Dr. Elena Castro (ES) addressed real-world treatment gaps and emphasized the growing adoption of intensified therapies.

In the SPCG-13 trial, Prof. Pirkko-Liisa Kellokumpu-Lehtinen (FI) reported no significant survival benefit from adding adjuvant docetaxel after radiotherapy, though a subset with high Gleason scores showed potential benefit. Discussant Dr. Alison Tree (GB) suggested ARPIs may offer better-tolerated alternatives, with ongoing trials expected to guide future strategies.

EAU 2025 was not only a celebration of innovation and scientific excellence but also a gathering of minds shaping the future of urology.

Our team at OncoDaily has also curated key highlights from EAU 2025 on social media that you won’t want to miss.

Guillermo de Andrés Boville:

“Today I had the privilege of presenting our TriNetX real-world evidence RwE abstract at the European Association of Urology (EAU25) Congress.

Our analysis included over 7,000 patients with high-risk and locally advanced prostate cancer LAPC— one of the largest cohorts of its kind. The findings suggest that upfront radical prostatectomy may offer improved oncological outcomes in terms of time to metastasis and overall survival.

It was an honor to share these results with the international urology community, and I’m grateful for the opportunity to contribute to the ongoing conversation around optimizing treatment strategies for this complex patient population.

Gran colaboración Gema Hernández Ibarburu!”

Sabine D. Brookman-May:

“How would a world without BCG look like?

Pros for BCG outlined by Gianluca Giannarini: efficacy, costs, and shortage are not a problem.

Counterpart addressed by Laura S. Mertens: maintenance is most critical to generate efficacy and toxicity not negligible.”

Muhammad Naseem Sherzad:

“Updated prostate cancer guidelines out. Nice move. European Association of Urology recommends splitting intermediate-risk localized disease into favorable and unfavorable (Any GGG3 and no cT3 or GGG2 with PSA 10-20).

However, the clinical stage is still based on DRE.”

Tyler Seibert:

“Mariluz Rojo presents RSIrs as a quantitative imaging biomarker for prostate cancer in about 2k patients from 7 centers.

Performance comparable to PI-RADS using an objective metric. Like a ‘lab test’ but with images of spatial location.”

Bertrand Tombal:

“Data from Peace3 presented by Fred Saad clearly suggest that early administration of bone protecting agent increase rPFS and OS in patients receiving enzalutamide +- Ra223.”

Sabine D. Brookman-May:

“Enjoyed the panel discussion with Shahrokh F. Shariat, Peter Black, and Laura Bukavina on the future development of the Virus-Like Drug Conjugate AU011 for the treatment of Bladder Cancer.

Phase 1 data are promising: 4/5 complete responses in IR target lesions.”

Zach Klaassen:

“ARANOTE: PSA response with Daro + ADT in patients with mHSPC.

Daro vs PBO

• 3x patients had PSA <0.2 at any time
• More patients had PSA <0.2 in high and low-volume subgroups

Daro PSA < 0.2 vs > 0.2

• rPFS: HR 0.19, 95% CI 0.13-0.27
• TT CRPC: HR 0.16, 95% CI 0.12-0.23
• TT PSA Prog: HR 0.08, 95% CI 0.05-0.12

PSA <0.2: More patients regardless of baseline PSA.”

Shilpa Gupta:

“Honored to be co-chair with Jeremy Teoh and S. Ziaran on the session “From prediction models to real-world outcomes in kidney cancer and urothelial cancer.”

Was very impressed with the quality of abstracts from all around the world highlighting the real world data and practices.

Kudos to European Association of Urology Congress organizers on arranging such a diverse range of important presentations and multi-D focus on oncologist care.”

Yüksel Ürün:

” EAU25 NIAGARA update.

In cisplatin-eligible MIBC, perioperative durvalumab improves outcomes:

• pCR↑ 10%
• EFS: HR 0.75
• OS: HR 0.68

No adverse impact on timing/rate of cystectomy or surgical complications!

Shaping a new standard!”

Alastair Lamb:

“Nice talk from Tarine Standgaard on tumor heterogeneity in NMIBC and uthe se of spatial transcriptomic (and bulk) analyses to distinguish BCG-responsive molecular subtype.

So glad to finally see the EAU lab up and running!

Thanks, EAU25 committee and ESUR.”

Félix Guerrero-Ramos:

“Brilliant presentation by Benjamin Pradere of the PENELOPE study at EAU25.

TAR-200 led to persistent tissue penetration of active gemcitabine metabolites across all layers of the bladder wall.”

Zach Klaassen:

“PEACE-3: Impact of BPAs on efficacy and safety of Enza vs Ra-223 + Enza

• med rPFS: 13 months without BPA increase to 27 months with BPA (HR 0.60, 95% CI 0.39-0.93)
• mOS: 26 months without BPA increase to 43 months with BPA (HR 0.56, 95%CI 0.37-0.86)
• mOS: Ra-223 + Enza + BPA = 72 months.”

The 41st Annual EAU Congress will take place in London, the United Kingdom on 13-16 March, 2026. Stay tuned to OncoDaily for more updates.